Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Neuphoria Therapeutics (NEUP) over the last 4 years, with Q4 2025 value amounting to $4.5 million.

  • Neuphoria Therapeutics' Shares Outstanding (Weighted Average) rose 18797.03% to $4.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 million, marking a year-over-year increase of 18797.03%. This contributed to the annual value of $1.6 million for FY2025, which is N/A changed from last year.
  • According to the latest figures from Q4 2025, Neuphoria Therapeutics' Shares Outstanding (Weighted Average) is $4.5 million, which was up 18797.03% from $2.2 million recorded in Q3 2025.
  • Neuphoria Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $981.6 million during Q2 2023, with a 5-year trough of $1.3 million in Q3 2024.
  • For the 4-year period, Neuphoria Therapeutics' Shares Outstanding (Weighted Average) averaged around $143.8 million, with its median value being $2.0 million (2025).
  • Within the past 5 years, the most significant YoY rise in Neuphoria Therapeutics' Shares Outstanding (Weighted Average) was 18797.03% (2025), while the steepest drop was 7276.57% (2025).
  • Quarter analysis of 4 years shows Neuphoria Therapeutics' Shares Outstanding (Weighted Average) stood at $156.1 million in 2021, then soared by 528.94% to $981.6 million in 2023, then tumbled by 99.84% to $1.6 million in 2024, then surged by 187.97% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q4 2025, $2.2 million for Q3 2025, and $1.6 million during Q2 2025.